Journal: Nature Communications
Article Title: Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8 + Tex subsets
doi: 10.1038/s41467-025-65615-0
Figure Lengend Snippet: a Experimental setup to assess the effects of αGal-9 or Galunisertib monotherapy and combination therapy in improving outcomes in B16F10-bearing C57BL/6 J mice with liver metastases. ( n = 6 mice, Vehicle + IgG; n = 6 mice, Galunisertib + IgG; n = 6 mice, Vehicle + αGal-9, n = 5 mice, Galunisertib + αGal-9). b Representative bioluminescent and macroscopic image of B16F10-bearing C57BL/6 J mice for indicated groups describe in ( a ). c Quantification of bioluminescence and LBR. d Survival curve of tumor-bearing mice for the indicated groups described in ( b ). Log-rank test for survival comparison. e Representative flow cytometry plots depicting the percentages of Tex subsets based on TCF1and CX3CR1. f Statistical analysis of ( e ). g Representative flow cytometry plots depicting the percentages of Tex subsets based on TOX/CX3CR1. h Statistical analysis of ( g ). i Representative flow cytometry plots based depicting the percentages of Tex subsets on Ki-67 and TCF1. j Statistical analysis of ( i ). k–m Representative flow cytometry plots ( k ) and statistical analysis ( l , m ) depicting the TNF and IFNγ co-production by CD8 + T cells upon ex vivo CD3/CD28 stimulation for the indicated groups. Data are presented as the mean ± SD, and were analyzed with one-way ( c , l , m ) or two-way ( f , h , g ) ANOVA with Sidak’s multiple comparison test. Consistent results were observed across three biological replicates in ( b–m ). Source data are provided as a Source Data file.
Article Snippet: The above findings prompted us to explore whether therapeutic interventions, specifically Galectin-9 neutralization (αGal-9) or TβRI inhibition (Galunisertib) , would similarly alleviate liver metastasis by reshaping CD8 + T cell responses in our mouse model.
Techniques: Comparison, Flow Cytometry, Ex Vivo